To empower the biomedical science community with cutting-edge proteomic technologies and advanced immune-profiling solutions that enable novel antigen discovery, accelerating disease understanding, diagnostics, and therapeutic development.

To create a new paradigm for immune profiling with unparalleled and unbiased antigen discovery technology, helping to expedite disease identification, accelerate the path to market for groundbreaking therapeutic interventions, and ultimately creating a low cost, routine diagnostic for patients everywhere.

Impact Proteomics is a biotechnology company that has developed the first truly unbiased platform technology for immune-profiling and antigen discovery with a patient-specific approach. Our patent-pending solution enables researchers across academia and industry to identify new therapeutic and diagnostic targets in a way that existing immunoassays cannot, given their inherent bias towards previously known targets. Founded by Carnegie Mellon University faculty, the company provides proteomic and multiomic sample preparation solutions, in addition to its core immune-profiling platform. 

Reflecting our academic roots, Impact Proteomics is a collaborative company that partners with customers and collaborators for a variety of use cases:

• Pharmaceutical and biopharmaceutical companies for target antigen/antibody identification & validation, in addition to patient stratification for clinical trials

• In Vitro Diagnostic (IVD) companies exploring new diagnostic protein markers or validating existing ones

• Academic and Non-profit disease research scientists seeking to identify novel disease-specific markers or complexes, or to validate existing hypotheses